Interim Analysis of the Effectiveness of Second-Line Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients Treated with Prior First-Line Treatment, Other Than Natalizumab, in Spain: The Observational, Retrospective NEXT Study (P3.106) | Publicación